amifostine anhydrous has been researched along with Atrial Fibrillation in 1 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation." | 5.15 | A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. ( Abboud, CN; Becker, MW; Bernstein, SH; Constine, LS; Friedberg, JW; Ifthikharuddin, JJ; Liesveld, JL; Loughner, JE; Milner, LA; Phillips, GL; Vesole, DH, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Phillips, GL | 1 |
| Bernstein, SH | 1 |
| Liesveld, JL | 1 |
| Abboud, CN | 1 |
| Becker, MW | 1 |
| Constine, LS | 1 |
| Ifthikharuddin, JJ | 1 |
| Loughner, JE | 1 |
| Milner, LA | 1 |
| Vesole, DH | 1 |
| Friedberg, JW | 1 |
1 trial available for amifostine anhydrous and Atrial Fibrillation
| Article | Year |
|---|---|
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carmus | 2011 |